

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B7, B8; Cw7, -; DR17, DR4; DQ2, DQ8

Summary of Results					Summary of Results					
Total tested	21	21	21	21	17	17	17	17		
Positive	4	2	2	9	0	0	0	0		
Negative	17	19	19	12	17	17	17	17		
Not Tested	2	2	2	2	2	2	2	2		
% Positive	19.0%	9.5%	9.5%	42.9%	0.0%	0.0%	0.0%	0.0%		
% Negative	81.0%	90.5%	90.5%	57.1%	100.0%	100.0%	100.0%	100.0%		
Consensus	Negative	Negative	Negative	Not Assessed	Negative	Negative	Negative	Negative		
HLA Antibody (Defined By CDC)	Cw4, Cw6	A24	B51	B17						
Lab No.	Without DTT				With DTT (Not assessed)				Comments	
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4		
9	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Samples NT due to staff shortages	
11	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
14	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
15	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative		
19	NT	NT	NT	NT	NT	NT	NT	NT		
20	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative		
23	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
24	NT	NT	NT	NT	NT	NT	NT	NT		
25	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Cells separated using Dynabeads. Unable to report T and B cell crossmatch for 2A06/2014 due to poor cell viability
28	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
34	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative		
35	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
38	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
39	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
41	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
42	Negative	Negative	Negative	Weak Positive	Negative	Negative	Negative	Negative		
45	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative		
48	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
51	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative		
54	Positive	Positive	Positive	Positive	Negative	Negative	Negative	Negative		
58	Weak Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
62	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative		

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 15TH JULY 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	0	0	0	2	0	0	0	0	04-Jun	05-Jun	Yes	Yes	90		Cedarlane	30	30	AO/PI
11									04-Jun	05-Jun	Yes	Yes	90		Cedarlane	45	90	Fluoroquencher
12	5%	5%	5%	5%	5%	5%	5%	5%	03-Jun	03-Jun	Yes	No	95		Cedarlane	30	90	EB/AO
14	0	0	0	0	0	0	0	0	04-Jun	04-Jun	Yes	Yes	90		Cedarlane	60	120	EB/AO
15	-	-	-	1	-	-	-	-	04-Jun	05-Jun	Yes	No	95		Cedarlane	60	60	EB/AO
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
20	1	1	1	2	1	1	1	1	04-Jun	05-Jun	Yes	No	95		Cedarlane	30	120	EB/AO
23	1	1	1	1					04-Jun	04-Jun		Yes	Yes	90	Cedarlane	40	40	EB/AO
24	NT	NT	NT	NT	NT	NT	NT	NT	04-Jun	05-Jun		Yes	Yes	60	Cedarlane	45	90	Fluoroquencher EB/AO
25	1	1	1	1	1	1	1	1	05-Jun	05-Jun		Yes	Yes	99	Cedarlane	45	60	Fluoroquencher
28	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	Yes	99	Cedarlane	30	45	EB/AO
34	6	-	-	6	-	-	-	-	04-Jun	04-Jun		Yes	Yes	95	Cedarlane	30	90	EB/AO
35	1	1	1	1	1	1	1	1	04-Jun	05-Jun	Yes	Yes	80	70	Cedarlane	45	90	Fluoroquencher
38	2	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes	Yes	99	95	Cedarlane	60	60	EB/AO
39	-	-	-	-	-	-	-	-	04-Jun	04-Jun	Yes	No	95		Cedarlane	45	90	EB/AO
41	0%	0%	0%	10%	0%	0%	0%	5%	04-Jun	04-Jun	Yes	Yes			Cedarlane	60	60	EB/AO
42	-	-	-	-	-	-	-	-	04-Jun	04-Jun	Yes	No	90		Cedarlane	60	120	EB/AO
45	1/2	4	4	6/8	1	1	1	1	04-Jun	05-Jun		Yes	Yes	99	Cedarlane	60	90	EB/AO
48	-	-	-	-	-	-	-	-	04-Jun	04-Jun	Yes	No	90		Cedarlane	30	60	Eosin/EB
51	0%	0%	0%	20-80%					04-Jun	05-Jun		Yes	Yes	95	Cedarlane	60	60	Fluoroquencher
54	25%	45%	45%	65%					04-Jun	05-Jun		Yes	Yes	>90	Cedarlane	60	60	PI
58	10%	5%	5%	5%	5%	5%	5%	5%	04-Jun	04-Jun	Yes	Yes	95		Cedarlane	60	90	Fluoroquencher
62	1	1	1	4					05-Jun	05-Jun	Yes	Yes	99		Cedarlane	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B7, B8; Cw7, -; DR17, DR4; DQ2, DQ8

Summary of Results					Summary of Results				
Total tested	17	17	17	16	13	13	13	12	
Positive	15	5	2	15	2	0	0	1	
Negative	2	12	15	1	11	13	13	11	
Not Tested	4	4	4	5	4	4	4	5	
% Positive	88.2%	29.4%	11.8%	93.8%	15.4%	0.0%	0.0%	8.3%	
% Negative	11.8%	70.6%	88.2%	6.3%	84.6%	100.0%	100.0%	91.7%	
Consensus	Positive	Not Assessed	Negative	Positive	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Cw4, Cw6	A24	B51	B17					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Positive	Negative	Negative	NT	Positive	Negative	Negative	NT	Serum 4 NT due to poor replicates
11	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
12	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Samples NT due to staff shortages
14	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
15	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Cells separated using Dynabeads. Unable to report T and B cell crossmatch for 2A06/2014 due to poor cell viability
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Poor cell viability. B cell crossmatch could not be assessed
23	Positive	Negative	Negative	Positive	NT	NT	NT	NT	
24	NT	NT	NT	NT	NT	NT	NT	NT	Tested but not reported. Cell viability too low. Lab policy requires minimum viability of 85%
25	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	NT	NT	NT	NT	NT	NT	NT	NT	Tested but not reported. Cell viability too low. Lab policy requires minimum viability of 85%
34	NT	NT	NT	NT	NT	NT	NT	NT	
38	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
39	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
41	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
42	Weak Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
45	Positive	Positive	Positive	Positive	Negative	Negative	Negative	Negative	
51	Positive	Negative	Negative	Positive					
54	Positive	Positive	Positive	Positive					
58	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
62	Positive	Negative	Negative	Positive					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 15TH JULY 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A06/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	2	0	0	-	2	0	0	-	04-Jun	05-Jun	Yes	90	Cedarlane	30	30	AO/PI
11	8	2		6					04-Jun	05-Jun	Yes	90		45	90	Fluoroquen
12	60%	10%	10%	80%	10%	10%	10%	10%	04-Jun	04-Jun	Yes	90	Cedarlane	30	60	EB/AO
14	8	2	0	8	0	0	0	0	04-Jun	04-Jun	Yes	90	Cedarlane	60	120	EB/AO
15	-	-	-	2	-	-	-	-	04-Jun	05-Jun	Yes	95	Cedarlane	60	60	EB/AO
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
20	2	1	1	9	1	1	1	1	04-Jun	05-Jun	Yes	95	Cedarlane	30	60	EB/AO
23	8	1	1	8					04-Jun	04-Jun	Yes	90	Cedarlane	40	40	EB/AO
24	NT	NT	NT	NT	NT	NT	NT	NT	04-Jun	05-Jun	Yes	40	Cedarlane	45	90	Fluoroquen EB/AO
25	1	1	1	1	1	1	1	1	05-Jun	05-Jun	Yes	99	Cedarlane	45	60	Fluoroquen
28	NT	NT	NT	NT	NT	NT	NT	NT	04-Jun	04-Jun	Yes	0	Cedarlane	30	45	EB/AO
34	NT	NT	NT	NT	NT	NT	NT	NT	04-Jun	04-Jun	Yes	60	Cedarlane	30	90	EB/AO
38	4	1	1	4	1	1	1	1	04-Jun	04-Jun	Yes	95	Cedarlane	60	60	EB/AO
39	6	2	-	6	-	-	-	-	04-Jun	04-Jun	Yes	95	Cedarlane	45	90	EB/AO
41	60%	0%	0%	40%	60%	0%	0%	40%	04-Jun	04-Jun	Yes	90	Cedarlane	45	45	EB/AO
42	20-40%	-	-	40-60%	-	-	-	-	04-Jun	04-Jun	Yes	90	TCS Biosciences	60	60	EB/AO
45	6-8	4	4	8	1	1	1	1	04-Jun	05-Jun	Yes	90	Cedarlane	30	75	EB/AO
51	40-80%	0%	0%	40-100%					04-Jun	05-Jun	Yes	90	Cedarlane	60	60	Fluoroquen
54	65%	25%	25%	65%					04-Jun	05-Jun	Yes	80	Cedarlane	60	60	PI
58	100%	5%	5%	90%	5%	55%	5%	5%	04-Jun	04-Jun	Yes	95	Cedarlane	60	90	Fluoroquen
62	8	1	1	8					05-Jun	05-Jun	Yes	95	Cedarlane	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate